Related Experiment Video

Updated: May 28, 2026

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease
04:23

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

Filovirus hemorrhagic fever outbreak case management: a review of current and future treatment options

Paul Roddy1, Robert Colebunders, Benjamin Jeffs

  • 1Médecins Sans Frontières-Spain, Barcelona, Spain. paul.roddy@barcelona.msf.org

The Journal of Infectious Diseases
|October 12, 2011
PubMed

Insights

Innovative therapies for filovirus hemorrhagic fever (FHF) are distant. This study discusses enhanced supportive care, including vital sign monitoring and intensive interventions, to improve FHF patient outcomes during outbreaks.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine

Background:

  • Filovirus hemorrhagic fever (FHF) outbreaks pose significant management challenges.
  • Current FHF case management relies on basic supportive treatment with limited evidence on best practices.
  • Innovative therapies for FHF are not yet available for outbreak settings.

Purpose of the Study:

  • To discuss potential improvements in FHF outbreak case management.
  • To explore comprehensive supportive treatment strategies beyond basic care.
  • To identify challenges and next steps for optimizing FHF patient outcomes.

Main Methods:

  • Literature review and expert discussion on FHF management.
  • Analysis of current supportive care practices.
  • Outline of potential enhanced treatment protocols.

Main Results:

  • Enhanced supportive care, including vital sign monitoring and intensive interventions, may improve clinical outcomes.
  • Feasibility and effectiveness of comprehensive supportive treatment require assessment.
  • Standardized protocols and collaborative platforms are needed for FHF outbreak management.

Conclusions:

  • More comprehensive supportive treatment holds promise for improving FHF patient outcomes.
  • Further research and assessment are needed to validate enhanced FHF care strategies.
  • Developing collaborative platforms and treatment protocols is crucial for future FHF outbreaks.

More Related Videos

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Related Concept Videos

Yellow Fever01:18

Yellow Fever

Yellow fever is a viral hemorrhagic disease caused by the yellow fever virus (YFV), a member of the Flaviviridae family. It is transmitted primarily by Aedes and Haemagogus mosquitoes in tropical and subtropical regions of Africa and South America. After transmission through a mosquito bite, the virus initially replicates in skin-resident immune cells such as dendritic cells and macrophages. These cells then migrate to the lymph nodes, where viral replication increases, eventually leading to...
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...